Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study
Martina Dragotto(University of Florence), Emanuele Trovato(University of Siena), Salvatore Panduri(University of Pisa), Michela Magnano(Ospedale Santa Chiara), Eugenio Capalbo(University of Siena), Federica Ricceri(Ospedale San Donato), Leonardo Pescitelli(University of Florence), Elia Rosi(Hidradenitis Suppurativa Foundation), Antonella Di Cesare(University of Florence), Alessandra Cartocci(University of Siena), Alessandra Michelucci(University of Pisa), Flavia Manzo Margiotta(Scuola Superiore Sant'Anna), Pietro Rubegni(University of Siena), Marco Romanelli(University of Pisa), Francesca Prignano(University of Florence), Nicola Milanesi(Ospedale del Ceppo), Susanna Rossari(University of Florence), Barbara Simoni(IMT School for Advanced Studies Lucca), Imma Savarese(University of Florence)
Cited by 8
Related Papers
Scanning the Immunopathogenesis of Psoriasis
|International Journal of Molecular Sciences|2018|317
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
|Autoimmunity Reviews|2015|198
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
|British Journal of Dermatology|2020|175
The Spectrum of Spitz Nevi
|Archives of Dermatology|2005|173
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
|Journal of Allergy and Clinical Immunology|2020|160